Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and ...

Good day and welcome to the Vertex Pharmaceuticals third-quarter 2024 earnings call. (Operator Instructions) Please note this event is being recorded. I would now like to turn the conference over to ...

Q3 2024 Earnings Call Transcript November 4, 2024 Vertex Pharmaceuticals Incorporated beats earnings expectations. Reported EPS is $4.38, expectations were $4.14. Operator: Good day. And welcome to ...

Operator Good day, and welcome to the Vertex Pharmaceuticals third quarter 2024 earnings call. All participants will be in a ...

led by povetacicept and AbbVie-partnered dual CD28 and ICOS inhibitor acazicolcept, which is in a phase 2 lupus trial, with results due later this year. Vertex has built its business on genetic ...

Vertex has been developing inhibitors to the NaV1.8 sodium channel for many years and previously abandoned other candidates because they were not selective enough for the target and inhibited ...

Scotiabank analyst Greg Harrison maintained a Buy rating on Geron (GERN – Research Report) today and set a price target of $6.00. The ...

Neurocrine Biosciences, Inc.'s potential for growth in the biopharma sector is strong despite recent setbacks, making its ...

Up until a couple of decades ago, hair loss was something that guys just had to accept and take in stride. Then came ...

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax ...

Nucleai, an AI-powered spatial biology company, will present two abstracts at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting. The presentations will detail how Nucleai's AI-driven ...